{
  "source": "PA-Notification-Alecensa.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1182-11\nProgram Prior Authorization/Notification\nMedication Alecensa® (alectinib)\nP&T Approval Date 5/2016, 3/2017, 8/2017, 8/2018, 9/2019, 9/2020, 8/2021, 8/2022, 8/2023,\n6/2024, 6/2025\nEffective Date 9/1/2025\n1. Background:\nAlecensa (alectinib) is a kinase inhibitor indicated for the treatment of adult patients with\nanaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) as\ndetected by an FDA-approved test and for adjuvant treatment in adult patients following tumor\nresection of ALK-positive NSCLC (tumors ≥ 4 cm or node positive) as detected by an FDA-\napproved test. The NCCN also recommends Alecensa for ALK-fusion\ntargeted relapsed/refractory, symptomatic Erdheim-Chester Disease, as second-line or initial\npalliative intent therapy and subsequent therapy for relapsed/refractory ALK+ anaplastic large\ncell lymphoma (ALCL), relapsed or refractory ALK-positive large B-Cell lymphoma, ALK-\npositive metastatic brain cancer from NSCLC, ALK-rearrangement positive pediatric diffuse\nhigh-grade glioma, and inflammatory myofibroblastic tumors with ALK translocation.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of\n19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Alecensa will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Non-Small Cell Lung Cancer (NSCLC)\n1. Initial Authorization\na. Alecensa will be approved based on all of the following cri",
    "t is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Non-Small Cell Lung Cancer (NSCLC)\n1. Initial Authorization\na. Alecensa will be approved based on all of the following criteria:\n(1) Diagnosis of non-small cell lung cancer (NSCLC)\n© 2025 UnitedHealthcare Services, Inc.\n1\n-AND-\n(2) Disease is anaplastic lymphoma kinase (ALK)-positive\n-AND-\n(3) One of the following:\n(a) Disease is one of the following:\ni. Recurrent\nii. Advanced\niii. Metastatic\n-OR-\n(b) Used as adjuvant treatment following tumor resection\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Alecensa will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Alecensa therapy\nAuthorization will be issued for 12 months.\nC. Histiocytic Neoplasms\n1. Initial Authorization\na. Alecensa will be approved based on all the following criteria:\n(1) Diagnosis of symptomatic Erdheim-Chester Disease\n-AND-\n(2) Used as targeted therapy ALK-fusion\n-AND-\n(4) Disease is one of the following:\n(a) Relapsed\n(b) Refractory\nAuthorization will be issued for 12 months.\n© 2025 UnitedHealthcare Services, Inc.\n2\n2. Reauthorization\na. Alecensa will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Alecensa therapy.\nAuthorization will be issued for 12 months.\nD. T-Cell Lymphomas\n1. Initial Authorization\na. Alecensa will be approved based on all the following criteria:\n(1) Diagnosis of anaplastic large cell lymphoma (ALCL)\n-AND-\n(2) Used as initial palliative intent therapy or second-line and subsequent therapy\n-AND-\n(3) Disease is one of the following:\n(a) Relapsed\n(b) Refractory\n-AND-\n(4) Anaplastic lymphoma kinase (ALK)-positive\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Alecensa will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Alecensa therapy.\nAuthorization will be issued for 12 mo",
    "authorization\na. Alecensa will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Alecensa therapy.\nAuthorization will be issued for 12 months.\nE. B-Cell Lymphomas\n1. Initial Authorization\na. Alecensa will be approved based on all the following criteria:\n(1) Diagnosis of large B-Cell lymphoma\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n3\n(2) Disease is one of the following:\n(a) Relapsed\n(b) Refractory\n-AND-\n(3) Anaplastic lymphoma kinase (ALK)-positive\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Alecensa will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Alecensa therapy.\nAuthorization will be issued for 12 months.\nF. Central Nervous System (CNS) Cancers / Pediatric Central Nervous System Cancers -\nPediatric Diffuse\n1. Initial Authorization\na. Alecensa will be approved based on both of the following criteria:\n(1) One of the following:\n(a) Diagnosis of metastatic brain cancer from NSCLC\n(b) Diagnosis of pediatric diffuse high-grade glioma\n-AND-\n(2) Tumor is anaplastic lymphoma kinase (ALK)-positive\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Alecensa will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Alecensa therapy\nAuthorization will be issued for 12 months.\nG. Soft Tissue Sarcoma/Uterine Neoplasms\n1. Initial Authorization\na. Alecensa will be approved based on both the following criteria:\n© 2025 UnitedHealthcare Services, Inc.\n4\n(1) Diagnosis of inflammatory myofibroblastic tumor (IMT)\n-AND-\n(2) Presence of ALK translocation\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Alecensa will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Alecensa therapy\nAuthorization will be issued for 12 months.\nH. NCCN Recommended Regimens\nThe drug has been recogniz",
    "owing criterion:\n(1) Patient does not show evidence of progressive disease while on Alecensa therapy\nAuthorization will be issued for 12 months.\nH. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category\nof Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Alecensa [package insert]. South San Francisco, CA: Genentech USA, Inc.; April 2024.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttp://www.nccn.org/professionals/drug_compendium/content/ . Accessed May 9, 2025.\n© 2025 UnitedHealthcare Services, Inc.\n5\nProgram Prior Authorization/Notification - Alecensa (alectinib)\nChange Control\n5/2016 New criteria.\n3/2017 Annual review, changed member to patient, with no change to criteria.\nUpdated references.\n8/2017 Updated background and criteria to include NCCN recommendation of\nfirst line use in ALK-positive metastatic or recurrent NSCLC. Updated\ncriteria formatting to align with other ALK NSCLC agents.\n8/2018 Updated background to include updated labeled indication for initial\ntherapy in metastatic ALK-positive NSCLC. Updated references.\n9/2019 Annual review with no changes to clinical coverage criteria. Updated\nreference. Added general NCCN recommended review criteria.\n9/2020 Annual review with no changes to c",
    "LC. Updated references.\n9/2019 Annual review with no changes to clinical coverage criteria. Updated\nreference. Added general NCCN recommended review criteria.\n9/2020 Annual review with no changes to clinical coverage criteria. Updated\nreference.\n8/2021 Annual review. Added advanced disease to criteria. Updated\nreferences.\n8/2022 Annual review. Updated background and references. Added criteria\nper NCCN recommendations for histiocytic neoplasms and t-cell\nlymphomas. Added state mandate footnote.\n8/2023 Annual review. Updated histiocytic neoplasm and T-Cell lymphoma\nformatting with no change to clinical criteria. Added criteria for B-Cell\nlymphoma, CNS cancer and IMT tumors per NCCN guidelines.\n6/2024 Added criteria for adjuvant treatment following tumor resection of\nALK-positive NSCLC per FDA label. Updated references.\n6/2025 Annual review. Added criteria for pediatric diffuse high-grade gliomas\nper NCCN guidelines. Updated background and references.\n© 2025 UnitedHealthcare Services, Inc.\n6"
  ]
}